Cdk5 is involved in NFT-like tauopathy induced by transient cerebral ischemia in female rats

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1772, Issue 4, 2007, Pages 473-483

  Wen, Yi ^a   Yang, Shao Hua ^a   Liu, Ran ^a   Perez, Evelyn J ^a   Brun Zinkernagel, Anne Marie ^a   Koulen, Peter ^a   Simpkins, James W ^a  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

CDK5; Hyperphosphorylated tau; Neurofibrillary tangle; Roscovitine; Tau; Tauopathy

Indexed keywords

CYCLIN DEPENDENT KINASE 5; PROTEIN P25; ROSCOVITINE; TAU PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INDUCTION; FEMALE; NEUROFIBRILLARY TANGLE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; TAUOPATHY; TRANSIENT ISCHEMIC ATTACK;

ANIMALS; CYCLIN-DEPENDENT KINASE 5; CYCLIN-DEPENDENT KINASES; DISEASE MODELS, ANIMAL; FEMALE; FUNCTIONAL LATERALITY; ISCHEMIC ATTACK, TRANSIENT; NEUROFIBRILLARY TANGLES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PURINES; RATS; RATS, SPRAGUE-DAWLEY; TAUOPATHIES;

MUS MUSCULUS; RATTUS; RODENTIA;

EID: 33947105676     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2006.10.011     Document Type: Article

References (74)

1. Lee V.M., Goedert M., and Trojanowski J.Q. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24 (2001) 1121-1159
2. Kondo J., Honda T., Mori H., Hamada Y., Miura R., Ogawara M., and Ihara Y. The carboxyl third of tau is tightly bound to paired helical filaments. Neuron 1 (1988) 827-834
3. Kosik K.S., Orecchio L.D., Binder L., Trojanowski J.Q., Lee V.M., and Lee G. Epitopes that span the tau molecule are shared with paired helical filaments. Neuron 1 (1988) 817-825
4. Lee V.M., Balin B.J., Otvos Jr. L., and Trojanowski J.Q. A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. Science 251 (1991) 675-678
5. Weingarten M.D., Lockwood A.H., Hwo S.Y., and Kirschner M.W. A protein factor essential for microtubule assembly. Proc. Natl. Acad. Sci. U. S. A. 72 (1975) 1858-1862
6. Cleveland D.W., Hwo S.Y., and Kirschner M.W. Purification of tau, a microtubule-associated protein that induces assembly of microtubules from purified tubulin. J. Mol. Biol. 116 (1977) 207-225
7. Neve R.L., Harris P., Kosik K.S., Kurnit D.M., and Donlon T.A. Identification of cDNA clones for the human microtubule-associated protein tau and chromosomal localization of the genes for tau and microtubule-associated protein 2. Brain Res. 387 (1986) 271-280
8. Goedert M., Wischik C.M., Crowther R.A., Walker J.E., and Klug A. Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proc. Natl. Acad. Sci. U. S. A. 85 (1988) 4051-4055
9. Trojanowski J.Q., and Lee V.M. Paired helical filament tau in Alzheimer's disease. The kinase connection. Am. J. Pathol. 144 (1994) 449-453
10. Goedert M., Jakes R., Spillantini M.G., Crowther R.A., Cohen P., Vanmechelen E., Probst A., Gotz J., and Burki K. Tau protein in Alzheimer's disease. Biochem. Soc. Trans. 23 (1995) 80-85
11. Billingsley M.L., and Kincaid R.L. Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration. Biochem. J. 323 (1997) 577-591
12. Buee L., Bussiere T., Buee-Scherrer V., Delacourte A., and Hof P.R. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Brain Res. Rev. 33 (2000) 95-130
13. Kanemaru K., K.akio T., Miura R., Titani K., and Ihara Y. Fetal-type phosphorylation of the tau in paired helical filaments. J. Neurochem. 58 (1992) 1667-1675
14. Biernat J., Gustke N., Drewes G., Mandelkow E.M., and Mandelkow E. Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding. Neuron 11 (1993) 153-163
15. Bramblett G.T., Goedert M., Jakes R., Merrick S.E., Trojanowski J.Q., and Lee V.M. Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding. Neuron 10 (1993) 1089-1099
16. Drechsel D.N., Hyman A.A., Cobb M.H., and Kirschner M.W. Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. Mol. Biol. Cell 3 (1992) 1141-1154
17. Drewes G., Lichtenberg-Kraag B., Doring F., Mandelkow E.M., Biernat J., Goris J., Doree M., and Mandelkow E. Mitogen activated protein (MAP) kinase transforms tau protein into an Alzheimer-like state. EMBO J. 11 (1992) 2131-2138
18. Hanger D.P., Hughes K., Woodgett J.R., Brion J.P., and Anderton B.H. Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci. Lett. 147 (1992) 58-62
19. Baumann K., Mandelkow E.M., Biernat J., Piwnica-Worms H., and Mandelkow E. Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5. FEBS Lett. 336 (1993) 417-424
20. Allen B., Ingram E., Takao M., Smith M.J., Jakes R., Virdee K., Yoshida H., Holzer M., Craxton M., Emson P.C., et al. Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J. Neurosci. 22 (2002) 9340-9351
21. Litersky J.M., and Johnson G.V. Phosphorylation by cAMP-dependent protein kinase inhibits the degradation of tau by calpain. J. Biol. Chem. 267 (1992) 1563-1568
22. Baudier J., and Cole R.D. Phosphorylation of tau proteins to a state like that in Alzheimer's brain is catalyzed by a calcium/calmodulin-dependent kinase and modulated by phospholipids. J. Biol. Chem. 262 (1987) 17577-17583
23. Singh T.J., Haque N., Grundke-Iqbal I., and Iqbal K. Rapid Alzheimer-like phosphorylation of tau by the synergistic actions of non-proline-dependent protein kinases and GSK-3. FEBS Lett. 358 (1995) 267-272
24. Hong M., Chen D.C., Klein P.S., and Lee V.M. Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. J. Biol. Chem. 272 (1997) 25326-25332
25. Lovestone S., Davis D.R., Webster M.T., Kaech S., Brion J.P., Matus A., and Anderton B.H. Lithium reduces tau phosphorylation: effects in living cells and in neurons at therapeutic concentrations. Biol. Psychiatry 45 (1999) 995-1003
26. Lew J., Huang Q.Q., Qi Z., Winkfein R.J., Aebersold R., Hunt T., and Wang J.H. A brain-specific activator of cyclin-dependent kinase 5. Nature 371 (1994) 423-426
27. Tatemichi T.K., Desmond D.W., Mayeux R., Paik M., Stern Y., Sano M., Remien R.H., Williams J.B., Mohr J.P., Hauser W.A., et al. Dementia after stroke: baseline frequency, risks, and clinical features in a hospitalized cohort. Neurology 42 (1992) 1185-1193
28. Loeb C., Gandolfo C., Croce R., and Conti M. Dementia associated with lacunar infarction. Stroke 23 (1992) 1225-1229
29. Tatemichi T.K., Paik M., Bagiella E., Desmond D.W., Stern Y., Sano M., Hauser W.A., and Mayeux R. Risk of dementia after stroke in a hospitalized cohort: results of a longitudinal study. Neurology 44 (1994) 1885-1891
30. Pasquier F., and Leys D. Why are stroke patients prone to develop dementia?. J. Neurol. 244 (1997) 135-142
31. Ikeda K., Akiyama H., Arai T., Kondo H., Haga C., Tsuchiya K., Yamada S., Murayama S., and Hori A. Neurons containing Alz-50-immunoreactive granules around the cerebral infarction: evidence for the lysosomal degradation of altered tau in human brain?. Neurosci. Lett. 284 (2000) 187-189
32. Shi J., Yang S.H., Stubley L., Day A.L., and Simpkins J.W. Hypoperfusion induces overexpression of beta-amyloid precursor protein mRNA in a focal ischemic rodent model. Brain Res. 85 (2000) 1-4
33. Contois J.H., Anamani D.E., and Tsongalis G.J. The underlying molecular mechanism of apolipoprotein E polymorphism: relationships to lipid disorders, cardiovascular disease, and Alzheimer's disease. Clin. Lab. Med. 16 (1996) 105-123
34. Dhavan R., and Tsai L.H. A decade of CDK5. Nat. Rev., Mol. Cell Biol. 2 (2001) 749-759
35. Hellmich M.R., Pant H.C., Wada E., and Battey J.F. Neuronal cdc2-like kinase: a cdc2-related protein kinase with predominantly neuronal expression. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 10867-10871
36. Tsai L.H., Takahashi T., Caviness Jr. V.S., and Harlow E. Activity and expression pattern of cyclin-dependent kinase 5 in the embryonic mouse nervous system. Development 119 (1993) 1029-1040
37. Lee M.S., Kwon Y.T., Li M., Peng J., M.riedlander FR., and Tsai L.H. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 405 (2000) 360-364
38. Patrick G.N., Zukerberg L., Nikolic M., de la Monte S., Dikkes P., and Tsai L.H. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402 (1999) 615-622
39. Simpkins J.W., Rajakumar G., Zhang Y.Q., Simpkins C.E., Greenwald D., Yu C.J., Bodor N., and Day A.L. Estrogens may reduce mortality and ischemic damage caused by middle cerebral artery occlusion in the female rat. J. Neurosurg. 87 (1997) 724-730
40. M.ise W.P., Dubal D.B., Wilson M.E., Rau S.W., and Bottner M. Minireview: neuroprotective effects of estrogen-New insights into mechanisms of action. Endocrinology 142 (2001) 969-973
41. Bremer A.M., Watanabe O., and Bourke R.S. Artificial embolization of the middle cerebral artery in primates. Description of an experimental model with extracranial technique. Stroke 6 (1975) 387-390
42. Gotz J., Chen F., van Dorpe J., and Nitsch R.M. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 293 (2001) 1491-1495
43. Gotz J., Chen F., Barmettler R., and Nitsch R.M. Tau filament formation in transgenic mice expressing P301L tau. J. Biol. Chem. 276 (2001) 529-534
44. Jiang W., Gu W., Brannstrom T., Rosqvist R., and Wester P. Cortical neurogenesis in adult rats after transient middle cerebral artery occlusion. Stroke 32 (2001) 1201-1207
45. Li Y., Chopp M., Powers C., and Jiang N. Apoptosis and protein expression after focal cerebral ischemia in rat. Brain Res. 765 (1997) 301-312
46. Jicha G.A., Bowser R., Kazam I.G., and Davies P. Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. J. Neurosci. Res. 48 (1997) 128-132
47. Takuma H., Arawaka S., and Mori H. Isoforms changes of tau protein during development in various species. Brain Res. Dev. Brain Res. 142 (2003) 121-127
48. Johnson G.V., and Bailey C.D. Tau, where are we now?. J. Alzheimer's Dis. 4 (2002) 375-398
49. Anderson A.J., Su J.H., and Cotman C.W. DNA damage and apoptosis in Alzheimer's disease: colocalization with c-Jun immunoreactivity, relationship to brain area, and effect of postmortem delay. J. Neurosci. 16 (1996) 1710-1719
50. Cotman C.W., and Su J.H. Mechanisms of neuronal death in Alzheimer's disease. Brain Pathol. 6 (1996) 493-506
51. Behl C. Apoptosis and Alzheimer's disease. J. Neural Transm. 107 (2000) 1325-1344
52. Smith M.A., Richey Harris P.L., Sayre L.M., Beckman J.S., and Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J. Neurosci. 17 (1997) 2653-2657
53. Slater A.F., Stefan C., Nobel I., van den Dobbelsteen D.J., and Orrenius S. Signalling mechanisms and oxidative stress in apoptosis. Toxicol. Lett. 82-83 (1995) 149-153
54. Yankner B.A. New clues to Alzheimer's disease: unraveling the roles of amyloid and tau. Nat. Med. 2 (1996) 850-852
55. Kratzsch T., Peters J., and Frolich L. Etiology and pathogenesis of Alzheimer dementia. Wien Med. Wochenschr. 152 (2002) 72-76
56. Gasparini L., Netzer W.J., Greengard P., and Xu H. Does insulin dysfunction play a role in Alzheimer's disease?. Trends Pharmacol. Sci. 23 (2002) 288-293
57. Kobayashi K., Nakano H., Hayashi M., Shimazaki M., Fukutani Y., Sasaki K., Sugimori K., and Koshino Y. Association of phosphorylation site of tau protein with neuronal apoptosis in Alzheimer's disease. J. Neurol. Sci. 208 (2003) 17-24
58. Su J.H., Anderson A.J., Cummings B.J., and Cotman C.W. Immunohistochemical evidence for apoptosis in Alzheimer's disease. NeuroReport 5 (1994) 2529-2533
59. Perry G., Nunomura A., Lucassen P., Lassmann H., and Smith M.A. Apoptosis and Alzheimer's disease. Science 282 (1998) 1268-1269
60. Lewis J., Dickson D.W., Lin W.L., Chisholm L., Corral A., Jones G., Yen S.H., Sahara N., Skipper L., Yager D., et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293 (2001) 1487-1491
61. Ishiguro K., Omori A., Takamatsu M., Sato K., Arioka M., Uchida T., and Imahori K. Phosphorylation sites on tau by tau protein kinase I, a bovine derived kinase generating an epitope of paired helical filaments. Neurosci. Lett. 148 (1992) 202-206
62. Tseng H.C., Zhou Y., Shen Y., and Tsai L.H. A survey of Cdk5 activator p35 and p25 levels in Alzheimer's disease brains. FEBS Lett. 523 (2002) 58-62
63. Pei J.J., Grundke-Iqbal I., Iqbal K., Bogdanovic N., Winblad B., and Cowburn R.F. Accumulation of cyclin-dependent kinase 5 (cdk5) in neurons with early stages of Alzheimer's disease neurofibrillary degeneration. Brain Res. 797 (1998) 267-277
64. Paudel H.K., Lew J., Ali Z., and Wang J.H. Brain proline-directed protein kinase phosphorylates tau on sites that are abnormally phosphorylated in tau associated with Alzheimer's paired helical filaments. J. Biol. Chem. 268 (1993) 23512-23518
65. Hashiguchi M., Saito T., Hisanaga S., and Hashiguchi T. Truncation of CDK5 activator p35 induces intensive phosphorylation of Ser202/Thr205 of human tau. J. Biol. Chem. 277 (2002) 44525-44530
66. Town T., Zolton J., Shaffner R., Schnell B., Crescentini R., Wu Y., Zeng J., DelleDonne A., Obregon D., Tan J., et al. p35/Cdk5 pathway mediates soluble amyloid-beta peptide-induced tau phosphorylation in vitro. J. Neurosci. Res. 69 (2002) 362-372
67. Li G., Faibushevich A., Turunen B.J., Yoon S.O., Georg G., Michaelis M.L., and Dobrowsky R.T. Stabilization of the cyclin-dependent kinase 5 activator, p35, by paclitaxel decreases beta-amyloid toxicity in cortical neurons. J. Neurochem. 84 (2003) 347-362
68. Tamura A., Gotoh O., and Sano K. Focal cerebral infarction in the rat: I. Operative technique and physiological monitorings for chronic model. No To Shinkei 38 (1986) 747-751
69. Green P.S., and Simpkins J.W. Neuroprotective effects of estrogens: potential mechanisms of action. Int. J. Dev. Neurosci. 18 (2000) 347-358
70. Wise P.M. Estrogens and neuroprotection. Trends Endocrinol. Metab. 13 (2002) 229-230
71. Choi D.W. Ischemia-induced neuronal apoptosis. Curr. Opin. Neurobiol. 6 (1996) 667-672
72. Love S. Oxidative stress in brain ischemia. Brain Pathol. 9 (1999) 119-131
73. Patzke H., and Tsai L.H. Calpain-mediated cleavage of the cyclin-dependent kinase-5 activator p39 to p29. J. Biol. Chem. 277 (2002) 8054-8060
74. Lee M.S., and Tsai L.H. Cdk5: one of the links between senile plaques and neurofibrillary tangles?. J. Alzheimer's Dis. 5 (2003) 127-137